SCHEMBL196966

SCHEMBL196966

Cc1cccc(-c2cccc(C)n2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 3/20 1.00
CCR8 P51685 2/20 1.00
METAP2 P50579 1/20 0.61
CYP2A6 P11509 1/20 0.56
NOS3 P29474 1/20 0.55
NOS2 P35228 1/20 0.55
TGFBR1 P36897 6/20 0.46
RAB9A P51151 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
ALOX15 P16050 2/20 0.42
CCR5 P51681 2/20 0.42
LMNA P02545 1/20 0.42
ALPL P05186 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ALPI P09923 1/20 0.42
ALPG P10696 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388304 1.00 CCR1 (1.00) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL30511194 1.00 CCR1 (1.00) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL29751933 0.97 CCR1 (0.94) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL3422291 0.97 CCR1 (0.94) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL29751919 0.97 CCR1 (0.94) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL20557390 0.97 CCR1 (0.94) CCR1CCR8METAP2CYP2A6NOS3
SCHEMBL3423401 0.97 CCR1 (0.94) CCR1CCR8METAP2CYP2A6NOS3
Hydrochloric Acid SCHEMBL2410509 0.94 CCR1 (0.89) CCR1CCR8METAP2CYP2A6NOS3
Bromide SCHEMBL4388984 0.94 CCR1 (0.89) CCR1CCR8METAP2CYP2A6NOS3
Iodide SCHEMBL4384044 0.94 CCR1 (0.89) CCR1CCR8METAP2CYP2A6NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 785 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250375458-A1 COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES THERALASE TECH INC (CA) 2025-12-11 US claimed
US-20250375511-A1 METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS THERALASE TECH INC (CA) 2025-12-11 US claimed
US-20250114456-A1 ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS THERALASE TECHNOLOGIES, INC. (CA) 2025-04-10 US claimed
EP-3042645-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2025-03-12 EP claimed
CN-117894971-B Glassy metal organic framework material modified ternary positive electrode material, and preparation method and application thereof 中南大学 2024-06-04 CN claimed
CN-117867526-A Preparation method of 2-deuterium-1, 2-diphenylethane derivative 五邑大学 2024-04-12 CN claimed
CN-117229234-A Preparation method of gamma-oxo ester and/or amide 中国科学院大连化学物理研究所 2023-12-15 CN claimed
CN-117229235-A Novel preparation method of naftidroflumilast 中国科学院大连化学物理研究所 2023-12-15 CN claimed
CN-116925012-A Preparation method of alpha-ester ether 中国科学院大连化学物理研究所 2023-10-24 CN claimed
CN-114853568-B Preparation method of 4, 5-pentafluoropentanol 辽宁孚音生物科技有限公司 2023-09-22 CN claimed
US-20100216988-A1 Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles SANOFI-AVENTIS (FR) 2010-08-26 US claimed
EP-2173721-A1 A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES Sanofi-Aventis (FR) 2010-04-14 EP claimed
EP-2173747-A1 A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES Sanofi-Aventis (FR) 2010-04-14 EP claimed
WO-2009000413-A1 A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI-AVENTIS (FR) 2008-12-31 WO claimed
WO-2009000412-A1 A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES SANOFI AVENTIS (FR) 2008-12-31 WO claimed
US-7238832-B2 Production method of a coupling compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-07-03 US claimed
EP-1449580-B1 Production method of a cross-coupling compound from an alkyl halide and an organoboron compound SUMITOMO CHEMICAL CO (JP) 2005-12-28 EP claimed
US-20040167364-A1 Production method of a coupling compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-26 US claimed
EP-1449580-A1 Production method of a cross-coupling compound from an alkyl halide and an organoboron compound Sumitomo Chemical Co.,Ltd. (JP) 2004-08-25 EP claimed
WO-2000053642-A1 CONTROLLED (CO)POLYMERISATION WITH N-HETEROCYCLES METAL COMPLEX SYSTEMS SCHUBERT ULRICH S (DE) 2000-09-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375458-A1 COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES CD4, TPMT, SLC11A2 CCR1 70/4885CCR8 193/4885METAP2 1883/4885
US-20250114456-A1 ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS PDCD1, CD47, CD274 CCR1 471/4885CCR8 903/4885METAP2 158/4885
US-20040167364-A1 Production method of a coupling compound PYM1, BRIX1, CXCR1 CCR1 94/4885CCR8 1500/4885METAP2 2894/4885
US-20250375511-A1 METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS NFATC1, PCNA, PHPT1 CCR1 2081/4885CCR8 3297/4885METAP2 396/4885
US-20100216988-A1 Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles AZI2, NIT2, NISCH CCR1 3957/4885CCR8 4506/4885METAP2 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.